Clinical trialNCT06465316RecruitingPhase 1Interventional

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

SponsorNational Cancer Institute (NCI)Enrollment26Recurrent Multiple MyelomaRefractory Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ricardo D Parrondo
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
Ricardo D. Parrondo
Recruiting
Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut, United States
Elan Gorshein
Recruiting
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut, United States
Elan Gorshein
Recruiting
Yale University
New Haven, Connecticut, United States
Elan Gorshein
Recruiting
Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut, United States
Elan Gorshein
Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, United States
Ricardo D. Parrondo
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Suspended
University of Kansas Cancer Center
Kansas City, Kansas, United States
Jeries Kort
Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, United States
Jeries Kort
Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
Jeries Kort
Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Ricardo D. Parrondo
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Srinivas S. Devarakonda
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Muhammad Salman Faisal
Recruiting
Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Hashim Mann
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Dec 2024
Primary completion: 31 Dec 2026
Completion: 31 Dec 2026
Last update posted: 30 Jun 2026
Registered enrollment: 26
Registry id: NCT06465316

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.